尿路上皮癌
化疗
医学
肿瘤科
内科学
癌症
膀胱癌
泌尿科
出处
期刊：Cancer Discovery
[American Association for Cancer Research]
日期：2021-03-04
卷期号：11 (5): OF8-OF8
标识
DOI：10.1158/2159-8290.cd-nb2021-0321
摘要
Enfortumab vedotin recently demonstrated greater efficacy than standard chemotherapy in patients with previously treated advanced urothelial cancer: In a phase III trial, the agent led to a median overall survival of 12.9 months, compared with 9 months in patients who received chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
GingerF
vc
学术文献互助
子车茗
chandangfo
pluto
贪玩的秋柔
科研狗
昏睡的蟠桃
殷勤的紫槐
漪涙
喷火娃
xjcy
Jry
畔畔
ephore
Twonej
大力的灵雁
pcr163
皖公网安备34019202002308
